The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).
 
Aaron Scott Mansfield
Honoraria - Roche
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst)
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Abbvie; Roche
 
Austin Goodrich
No Relationships to Disclose
 
Nathan R. Foster
No Relationships to Disclose
 
Vinicius Ernani
No Relationships to Disclose
 
Patrick M. Forde
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; F-Star Biotechnology; G1 Therapeutics; Genentech; ITeos Therapeutics; Janssen; Novartis; Sanofi; Surface Oncology
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals; Kyowa Hakko Kirin (Inst); Novartis (Inst)
 
Liza C Villaruz
Consulting or Advisory Role - Achilles Therapeutics; Bristol-Myers Squibb/Celgene; Daiichi Sankyo/Astra Zeneca; Janssen Oncology; Jazz Pharmaceuticals; Takeda
Research Funding - AstraZeneca (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); BMS (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Rain Therapeutics (Inst); Regeneron (Inst)
 
Kanwal Pratap Singh Raghav
Consulting or Advisory Role - AstraZeneca; Bayer; Daiichi Sankyo; Eisai
Speakers' Bureau - Bayer
Research Funding - Bayer (Inst); Daiichi Sankyo/Lilly (Inst); Guardant Health (Inst); Roche/Genentech (Inst)
 
Paul Bernard Romesser
Stock and Other Ownership Interests - Pfizer
Consulting or Advisory Role - EMD Serono
Research Funding - EMD Serono
Travel, Accommodations, Expenses - Elekta
 
Krista Garbacz
No Relationships to Disclose
 
Liang Cao
No Relationships to Disclose
 
Mary M. Salvatore
Honoraria - Boehringer Ingelheim; Eastern Pulmonary Conference; Genentech; Rockpointe CME
Consulting or Advisory Role - Boehringer Ingelheim; Boehringer Ingelheim
Speakers' Bureau - Boehringer Ingelheim; Genentech
Research Funding - Boehringer Ingelheim (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Eastern Pulmonary Conference; Genentech; Rockpointe CME
 
Anja Roden
No Relationships to Disclose
 
Steven Francis Powell
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
Research Funding - Actuate Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Vyriad (Inst)
 
Ardaman Shergill
Honoraria - Cholangiocarcinoma Foundation; cholangiocarcinoma summit; Curio Science; oklahoma society of clinical oncology; OncLive/MJH Life Sciences; saint joseph hospital Chicago
Consulting or Advisory Role - Catalyst Pharmaceuticals; KLJ Associates; Triptych Health Partners
Research Funding - Gossamer Bio (Inst); Gritstone Bio (Inst); Hutchison MediPharma (Inst); Merck (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); TP Therapeutics (Inst); verastem (Inst)
 
Pamela N. Munster
Leadership - Alessa Therapeutics; EpiAxis Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics; AtlasMedx; OnKure
Honoraria - Alkermes; AstraZeneca/Merck; Athenex; GlaxoSmithKline; Olema Pharmaceuticals
Consulting or Advisory Role - Alessa Therapeutics; AtlasMedx; BeiGene; Olema Pharmaceuticals; RasCal
Research Funding - Actuate Therapeutics (Inst); Amgen (Inst); Arch Oncology (Inst); Arvinas (Inst); Bliss Biopharmaceutical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Cyteir; Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Immune Design (Inst); Merck (Inst); Novartis (Inst); oncosec (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Sanofi (Inst); Tempest Therapeutics (Inst); Tesaro/GSK (Inst); Xynomic Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents
 
Gary K. Schwartz
Stock and Other Ownership Interests - Bionaut Labs; GenCirq; January Therapeutics
Consulting or Advisory Role - Apexigen; Array BioPharma; Astex Pharmaceuticals; Bionaut Labs; Concarlo; Ellipses Pharma; Epizyme; Gencirq; January Therapeutics; Oncogenuity; OnCusp Therapeutics; PureTech; Sellas Life Sciences; Shanghai Pharma
Research Funding - Adaptimmune (Inst); Astex Pharmaceuticals; Astex Pharmaceuticals (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Fortress Biotech (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Oxford BioTherapeutics (Inst); SpringWorks Therapeutics (Inst); TopAlliance BioSciences Inc (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Array BioPharma; Epizyme; Epizyme; Epizyme
 
Travis Edward Grotz
No Relationships to Disclose